

HYPERA S.A.

A Publicly-Held Corporation

CNPJ No. 02.932.074/0001-91

NIRE 35.300.353.251

Code CVM No. 21431

NOTICE TO THE MARKET

HYPERA S.A. (“Company” or “Hypera Pharma”), in compliance with the provisions of Article 157, paragraph 4, of Law No. 6,404, of December 15, 1976, as amended, and of the Brazilian Securities Commission (“CVM”) Rule No. 358, of January 3, 2002, as amended, informs its shareholders and the market in general that it has entered into an investment agreement for the acquisition of a minority equity interest in **Consulta Remédios**, of 22.5% of its capital stock, with the possibility of increasing such minority interest, being the conclusion of the transaction subject to the compliance with certain conditions precedent.

Consulta Remédios (“www.consultaremedios.com.br”) is the largest platform for accessing and consulting pharmaceutical products information in Brazil and the 5th largest pharmaceutical portal in the world in number of visitors. With presence in all regions of the country, Consulta Remédios operates in partnership with large and medium-sized pharmaceutical retail chains, and today has approximately 1 million unique visitors daily.

This is the second investment of Hypera Ventures, a corporate venture capital initiative that seeks to invest in startups linked to the health and wellness sector that have synergies with Hypera Pharma’s business. This movement is in line with the Company’s strategic objective of accelerating its investments in technology and digital platforms in order to continuously increase its proximity to its end consumers, understanding their consumption habits with the purpose of boosting sales and promoting quality health to the Brazilian population.

São Paulo, April 16, 2021.

HYPERA S.A.

Adalmario Ghovatto Satheler do Couto

Investor Relations Officer